Type 2 Diabetes Connect
  • Saved

2yr
The effectiveness of social media-based microlearning in improving knowledge, self-efficacy, and self-care behaviors among adult patients with type 2 diabetes: an educational intervention

The effectiveness of social media-based microlearning in improving knowledge, self-efficacy, and self-care behaviors among adult patients with type 2 diabetes: an educational intervention

Source : https://pubmed.ncbi.nlm.nih.gov/38937738/

In conclusion, the SMBM appears to be an effective tool for improving self-efficacy, self-care, and knowledge among patients with type 2 diabetes.

The SMBM appears to be an effective tool for improving self-efficacy, self-care, and knowledge among patients with type 2 diabetes.

  • Saved

2yr
Ameliorating and refining islet organoids to illuminate treatment and pathogenesis of diabetes mellitus

Ameliorating and refining islet organoids to illuminate treatment and pathogenesis of diabetes mellitus

Source : https://pubmed.ncbi.nlm.nih.gov/38937834/

Diabetes mellitus, a significant global public health challenge, severely impacts human health worldwide. The organoid, an innovative in vitro three-dimensional (3D) culture model, closely mimics tissues or organs in vivo....

This review delves into the methodologies and strategies for constructing the islet organoid, its application in diabetes treatment, and the pivotal scientific challenges within organoid research, offering fresh perspectives for a deeper understanding of diabetes pathogenesis and the development of therapeutic interventions.

  • Saved

2yr
The effects of vitamin D supplementation on serum lipid profiles in people with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

The effects of vitamin D supplementation on serum lipid profiles in people with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

Source : https://pubmed.ncbi.nlm.nih.gov/38903615/

https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=461136.

This meta-analysis highlighted the effects of vitamin D supplementation on improving serum HDL and TG levels while not exhibiting significant improvements in LDL and TC levels. Further long-term and high-quality studies are still needed to draw more precise conclusions.

  • Saved

2yr
Emerging Roles and Therapeutic Applications of Arachidonic Acid Pathways in Cardiometabolic Diseases

Emerging Roles and Therapeutic Applications of Arachidonic Acid Pathways in Cardiometabolic Diseases

Source : https://pubmed.ncbi.nlm.nih.gov/38900855/

Cardiometabolic disease has become a major health burden worldwide, with sharply increasing prevalence but highly limited therapeutic interventions. Emerging evidence has revealed that arachidonic acid derivatives and pathway factors link...

Significant advances have been made in understanding AA pathways and their participation in cardiometabolic diseases. Despite the clear facts supporting AA pathway factors as exact sensors and contributors to cardiometabolic pathologies via specific biological mechanisms, there are several important questions to be addressed. To move the...

  • Saved

2yr
Interplay between type 2 diabetes, CVD, and CKD

The metabolic, cardiac, and renal systems share a symbiotic relationship. The heart relies on the metabolic system for energy and the kidneys for volume maintenance. The kidneys rely on the heart for perfusion and the metabolic system for hormones to support function. In turn, the metabolic system depends on proper functioning of the heart and kidneys to prevent neurohormonal activation leading to insulin resistance, glycose dysregulation, and dyslipidemia.

Given this interrelationship, type 2 diabetes often coexists with CVD and CKD. Moreover, CVD and CKD in the presence of type 2 diabetes worsen each other, thereby amplifying morbidity and mortality. Accordingly, the American Diabetes Association (ADA) asserts that the treatment goal for type 2 diabetes is not only glycemic and weight management but also cardiorenal risk reduction.

The ADA recommends sodium-glucose transport protein 2 (SGLT2) inhibitors as glucose-lowering agents with proven cardiorenal benefits. Some of these agents reduce the risk of CV events in patients with type 2 diabetes and an elevated risk of CVD, although another agent in this class increases the risk of amputation. Some of the agents in this class have cardiac benefits in patients with heart failure, with or without comorbid type 2 diabetes. Several SGLT2 inhibitors in this class also have renal benefits in patients with CKD (with or without type 2 diabetes), whereas another in the class slows the progression of diabetic kidney disease.

When would you prescribe this class of medication for your patients with type 2 diabetes?

  • 2yr
    I prescribe SGLT-2 inhibitors regularly for my diabetic patients because I appreciate both the cardiac and renal benefits, in addition to the glycemic benefits. Given that the risk of hypoglycemia Show More
  • 2yr
    Given these benefits, I might consider prescribing SGLT2 inhibitors for patients who need additional glycemic control despite lifestyle modifications and other antidiabetic medications, and particularly for those with existing cardiovascular Show More

Show More Comments